VKTX Beats on Q3 Earnings, Stock Up on Obesity Pipeline Advancements

Viking Therapeutics (VKTX) reported third-quarter 2024 loss per share of 22 cents, narrower than the Zacks Consensus Estimate of a loss of 24 cents. The company had incurred a loss of 23 cents per share in the year-ago quarter.Currently, Viking Therapeutics does not have any approved product in its portfolio. Hence, it is yet to generate revenues.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.More on VKTX’s Q3 EarningsResearch and development expenses totaled $22.8 million, up 24% ...